Last reviewed · How we verify
NCT05508698
Flu Shot Pre-visit Questionnaire
NA trial testing Precommitment Nudge in Influenza in 230,962 participants. Completed in 8 April 2023.
8 April 2023
Quick facts
| Lead sponsor | Geisinger Clinic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 230,962 |
| Start date | 18 August 2022 |
| Primary completion | 8 April 2023 |
| Estimated completion | 8 April 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Precommitment Nudge
- Salience
Conditions studied
- Influenza — all drugs for Influenza →
Sponsor
Geisinger Clinic
Who can join
18 and older, any sex, with Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess, prospectively, the effect on flu vaccination rates of a pre-visit questionnaire that asks patients to indicate their preferences for a flu shot. Responses to the questionnaire will also be shown to clinicians via additional text in an existing flu shot alert. The investigators hypothesize that the pre-visit questionnaire will lead to increased flu vaccination compared with standard practices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05508698
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Influenza
Currently open trials in the same condition.
- NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
Other Geisinger Clinic trials
Trials by the same sponsor.
- NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
- NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
- NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
- NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
- NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05508698 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
- Last refreshed: 25 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05508698.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing